Skip to main contentSkip to navigationSkip to search

Curasight A/S receives approximately DKK 47.6 million through exercise of warrants of series TO 1

October 11, 2021


On Thursday, 7 October 2021, the exercise period for Curasight A/S (“Curasight” or “the Company”) warrants of series TO 1 (“TO 1”) ended. A total of 2,767,551 warrants of series TO 1 were exercised. Curasight will thus receive a total of approximately DKK 47.6 million before issue costs.

CEO Ulrich Krasilnikoff comments

“We are very grateful for the confidence shown in the completed exercise of warrants of series of TO 1. The raised capital is important for Curasight’s future development plans within diagnosis and treatment of cancer patients. Curasight is now in a good financial position, which will accelerate the plan and unlock the full potential of our platform.”

Total exercise, number of shares and share capital

In total, 2,767,551 warrants of series TO 1 have been exercised, corresponding to a subscription rate of approximately 97.6 percent. Through the warrants of series TO 1, the Company will receive approximately DKK 47.6 million before issue costs, which are estimated to amount to DKK 3 million. When the shares from the exercise of TO 1 are registered with the Danish Companies Registration Office, the total number of shares will amount to 19,893,891 and the share capital will amount to DKK 994,694.55. The planned date for conversion from interim shares to common shares is expected to take place on the 15 October 2021 and the common shares are expected to be visible in each subscriber’s account around the 19 October 2021.

This information is such information that Curasight A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the above contact person, for publication on 11 October 2021.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60


Curasight A/S is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.